The FDA approved icotrokinra for adults and adolescents aged 12 years and older with moderate to severe plaque psoriasis, ...

This is the first IL-23 receptor-targeted oral peptide pill, and it is also being evaluated as a treatment for psoriatic arthritis, ulcerative colitis, and Crohn’s disease.

ICOTYDE is the first and only IL-23R targeted oral peptide that delivers complete skin clearance and a favorable safety profile in a once-daily pill Approval supported by four phase 3 studies that met ...

FDA authorization covers moderate-to-severe plaque psoriasis in adults and patients aged ≥12 years, expanding systemic options for adolescents. Icotrokinra is characterized as a first-in-class ...

The U.S. Food and Drug Administration on Wednesday approved Johnson & Johnson's oral pill for psoriasis, the company said.

84% of adolescents with moderate-to-severe plaque psoriasis treated with investigational icotrokinra achieved clear or almost clear skin (IGA 0/1) at Week 16 ICONIC-LEAD is the first ever Phase 3 ...

Laser therapy plus topical effective for generalized plaque psoriasis Combination treatment avoids side effects often seen with systemic therapy. Ethan C. Levin, MD, Psoriasis and Skin Treatment ...

Psoriasis treatments have been a staple of TV advertising for nearly 50 years. That’s because the skin disease is relatively widespread throughout the United States. Roughly 80 to 90 percent of ...

Although some people with plaque psoriasis can control their symptoms by using topical treatments that are applied to the skin, some people with moderate or severe plaque psoriasis do not get enough ...

Since revealing her plaque psoriasis diagnosis in 2015, La La Anthony has become a powerful voice for those living with the chronic skin condition. Plaque psoriasis—often mistaken for dry skin or ...

Oral icotrokinra is now FDA-approved for plaque psoriasis, offering a new systemic option for adults and adolescents who weigh at least 40kg.